Cyclin-Dependent Kinase Inhibitor AT7519 As a Potential Drug for MYCN-Dependent Neuroblastoma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2015 Jul 24

PMID 26202950

Citations 27

Authors

M Emmy M Dolman

Evon Poon

Marli E Ebus

Ilona J M den Hartog

Carel J M van Noesel

Yann Jamin

Albert Hallsworth

Simon P Robinson

Kevin Petrie

Rolf W Sparidans

Robbert J Kok

Rogier Versteeg

Huib N Caron

Louis Chesler

Jan J Molenaar

Affiliations

Soon will be listed here.

Abstract

Purpose: MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous preclinical studies, we have shown that targeted inhibition of cyclin-dependent kinase 2 (CDK2) resulted in specific killing of MYCN-amplified neuroblastoma cells. This study describes the in vivo preclinical evaluation of the CDK inhibitor AT7519.

Experimental Design: Preclinical drug testing was performed using a panel of MYCN-amplified and MYCN single copy neuroblastoma cell lines and different MYCN-dependent mouse models of neuroblastoma.

Results: AT7519 killed MYCN-amplified neuroblastoma cell lines more potently than MYCN single copy cell lines with a median LC50 value of 1.7 compared to 8.1 μmol/L (P = 0.0053) and a significantly stronger induction of apoptosis. Preclinical studies in female NMRI homozygous (nu/nu) mice with neuroblastoma patient-derived MYCN-amplified AMC711T xenografts revealed dose-dependent growth inhibition, which correlated with intratumoral AT7519 levels. CDK2 target inhibition by AT7519 was confirmed by significant reductions in levels of phosphorylated retinoblastoma (p-Rb) and nucleophosmin (p-NPM). AT7519 treatment of Th-MYCN transgenic mice resulted in improved survival and clinically significant tumor regression (average tumor size reduction of 86% at day 7 after treatment initiation). The improved efficacy of AT7519 observed in Th-MYCN mice correlated with higher tumor exposure to the drug.

Conclusions: This study strongly suggests that AT7519 is a promising drug for the treatment of high-risk neuroblastoma patients with MYCN amplification.

Citing Articles

3-chymotrypsin-like protease in SARS-CoV-2.

Al Adem K, Ferreira J, Villanueva A, Fadl S, El-Sadaany F, Masmoudi I Biosci Rep. 2024; 44(8).

PMID: 39036877 PMC: 11300678. DOI: 10.1042/BSR20231395.

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.

CDK9 inhibitors in cancer research.

Huang Z, Wang T, Wang C, Fan Y RSC Med Chem. 2022; 13(6):688-710.

PMID: 35814933 PMC: 9215160. DOI: 10.1039/d2md00040g.

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma.

Wang H, Wang X, Xu L, Zhang J BMC Genom Data. 2022; 23(1):41.

PMID: 35655142 PMC: 9164562. DOI: 10.1186/s12863-022-01059-5.

Targeting MYCN and ALK in resistant and relapsing neuroblastoma.

Tucker E, Poon E, Chesler L Cancer Drug Resist. 2022; 2(3):803-812.

PMID: 35582571 PMC: 8992505. DOI: 10.20517/cdr.2019.009.

References

Squires M, Feltell R, Wallis N, Lewis E, Smith D, Cross D . Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009; 8(2):324-32. DOI: 10.1158/1535-7163.MCT-08-0890. View

Twentyman P, LUSCOMBE M . A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987; 56(3):279-85. PMC: 2002206. DOI: 10.1038/bjc.1987.190. View

Molenaar J, Ebus M, Geerts D, Koster J, Lamers F, Valentijn L . Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A. 2009; 106(31):12968-73. PMC: 2695754. DOI: 10.1073/pnas.0901418106. View

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8(6):e1000412. PMC: 2893951. DOI: 10.1371/journal.pbio.1000412. View

Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop J . Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A. 2010; 107(31):13836-41. PMC: 2922232. DOI: 10.1073/pnas.1008366107. View

Cole K, Huggins J, LaQuaglia M, Hulderman C, Russell M, Bosse K . RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011; 108(8):3336-41. PMC: 3044382. DOI: 10.1073/pnas.1012351108. View

Chan D, Giaccia A . Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011; 10(5):351-64. PMC: 3652585. DOI: 10.1038/nrd3374. View

Teitz T, Stanke J, Federico S, Bradley C, Brennan R, Zhang J . Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One. 2011; 6(4):e19133. PMC: 3084749. DOI: 10.1371/journal.pone.0019133. View

10.

Mahadevan D, Plummer R, Squires M, Rensvold D, Kurtin S, Pretzinger C . A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol. 2011; 22(9):2137-2143. DOI: 10.1093/annonc/mdq734. View

11.

Murga M, Campaner S, Lopez-Contreras A, Toledo L, Soria R, Montana M . Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011; 18(12):1331-1335. PMC: 4894468. DOI: 10.1038/nsmb.2189. View

12.

Chanthery Y, Gustafson W, Itsara M, Persson A, Hackett C, Grimmer M . Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med. 2012; 4(115):115ra3. PMC: 3402217. DOI: 10.1126/scitranslmed.3002977. View

13.

Lamers F, Schild L, Koster J, Versteeg R, Caron H, Molenaar J . Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer. 2011; 48(5):763-71. DOI: 10.1016/j.ejca.2011.10.012. View

14.

Toyoshima M, Howie H, Imakura M, Walsh R, Annis J, Chang A . Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012; 109(24):9545-50. PMC: 3386069. DOI: 10.1073/pnas.1121119109. View

15.

Valentijn L, Koster J, Haneveld F, Aissa R, van Sluis P, Broekmans M . Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A. 2012; 109(47):19190-5. PMC: 3511149. DOI: 10.1073/pnas.1208215109. View

16.

Jamin Y, Tucker E, Poon E, Popov S, Vaughan L, Boult J . Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology. 2012; 266(1):130-40. PMC: 4298658. DOI: 10.1148/radiol.12120128. View

17.

Quarta C, Cantelli E, Nanni C, Ambrosini V, DAmbrosio D, Di Leo K . Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. Mol Imaging Biol. 2012; 15(2):194-202. PMC: 3594000. DOI: 10.1007/s11307-012-0576-9. View

18.

Misra R, Xiao H, Kim K, Lu S, Han W, Barbosa S . N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem. 2004; 47(7):1719-28. DOI: 10.1021/jm0305568. View

19.

Delehouze C, Godl K, Loaec N, Bruyere C, Desban N, Oumata N . CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 2013; 33(50):5675-87. PMC: 4087096. DOI: 10.1038/onc.2013.513. View

20.

Weiss W, Aldape K, Mohapatra G, Feuerstein B, Bishop J . Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997; 16(11):2985-95. PMC: 1169917. DOI: 10.1093/emboj/16.11.2985. View